查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1247468

2023-2030 年全球生命科學儀器市場

Global Life Science Instrumentation Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球生命科學儀器市場預計到 2022 年將達到 560 億美元，到 2030 年將達到 1070 億美元。 在預測期內（2023-2030 年），該市場將以 7.9% 的複合年增長率增長。

為了最大限度地提高產量並保持過程控制，生命科學，尤其是生物技術、製藥和醫療設備，需要可靠且準確的儀器。 用於調節和監控過程以及評估製造工廠的產品質量的儀器被稱為生命科學儀器。 它通常被視為物理學、工程學和生物科學的融合。 在生物技術領域，它是分子生物學和生物體科學研究的重要工具。

市場動態

藥物研發投入增加。

生物技術和製藥等公司正在大力投資研發。 這是由對快速藥物開發和用於治療罕見疾病的新型藥理化合物商業化的日益增長的需求所推動的。

世界的疾病負擔和不斷上升的研發成本從根本上推動了對生命科學儀器的需求。 此外，製藥行業增加對藥物發現和開發的投資將增加對用於藥物驗證的生命科學工具的需求。 增加對生命科學研究的公共和私人投資以及分析儀器技術的進步正在推動生命科學儀器和化學品的市場。

例如，根據英國議會在2022年10月發布的一篇文章，英國在2022年的研發支出總額為375億歐元。 此外，根據經合組織數據，2021年藥品佔GDP的比重將在保加利亞最高，約為33.0%。 因此，由於研發活動的醫藥支出增加，預計市場將擴大。

某些類型的癌症產品可以使用基於生命科學設備的藥物進行有效治療。 這可以降低發展中國家和欠發達國家的醫療保健成本。 隨著全球癌症患者數量的增加，生命科學儀器市場有望增長。

設備的高成本可能會阻礙市場增長。

生命科學儀器市場的發展將受到儀器成本高、缺乏合格勞動力、qPCR 和 dPCR 程序的技術限制以及高性能顯微鏡的高成本的限制。 另一方面，新興國家缺乏研究基礎設施和價格壓力可能會威脅到市場擴張。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按產品分類的片段
  • 按技術分類的片段
  • 區域摘要

第 4 章動力學

  • 影響因子
    • 司機
      • 擴大對生命科學研究的公私合作資助
      • 慢性病越來越普遍
    • 約束因素
      • 設備成本高阻礙了市場增長
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章技術

  • 光譜學
  • 聚合□鍊式反應 (PCR)
  • 色譜法
  • 流式細胞儀
  • 電泳
  • 離心機
  • 其他

第八章應用

  • 調查
  • 臨床/診斷

第 9 章：結束

  • 製藥和生物技術公司
  • 農業和食品行業
  • 醫院/診斷中心

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 俄羅斯
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 競爭場景
  • 市場分析/份額分析
  • 併購分析

第12章公司簡介

  • Bio-Rad 實驗室公司
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展
  • Agilent Technologies Inc
  • PerkinElmer, Inc
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • JEOL Ltd
  • Shimadzu Corporation
  • Becton, Dickinson & Company
  • HORIBA, Ltd.,
  • Bruker Corporation

第13章 附錄

簡介目錄
Product Code: MD1529

Market Overview

The global Life Science Instrumentation market reached US$ 56,000 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 107,000 million by 2030. The market is growing at a CAGR of 7.9% during the forecast period (2023-2030).

To maximize yields and maintain process control, life sciences, particularly biotechnology, pharmaceuticals, and medical devices, need dependable and accurate instrumentation. The equipment used to regulate and monitor the process in manufacturing plants, as well as to assess the quality of the products, is known as life science instrumentation. It is generally seen as the fusion of physics, engineering, and biological sciences. In the realm of biotechnology, these tools are essential for the scientific examination of molecular biology and living things.

Market Dynamics

The increasing investments spending on pharmaceutical research and development.

In companies like biotechnology and pharmaceuticals, there is a large investment in R&D. The increased desire for quick medication development and the commercialization of novel pharmacological compounds for the treatment of uncommon illnesses are to blame for this.

The burden of illness in the world and rising R&D costs are what essentially drive the demand for life science devices. Also, there will likely be a rise in demand for life science tools for drug validation due to the pharmaceutical industry's growing investment in drug discovery and development. Growing public-private investments in life science research as well as advancements in analytical equipment technology are driving the market for life science instruments and chemicals.

For instance, according to an article released by the UK Parliament in October 2022, the UK spent a total of EUR 37.5 billion on research and development in 2022. Also, according to OECD data, Bulgaria spent the most on pharmaceuticals as a proportion of GDP in 2021, at about 33.0%. Hence, it is anticipated that market expansion will be aided by rising pharmaceutical spending on R&D activities.

A certain Product of cancer can be effectively treated using drugs based on Life Science Instrumentation. This lowers the cost of healthcare for developing and underdeveloped nations. The Life Science Instrumentation market should grow as cancer cases rise globally.

The high cost of instruments will hamper the growth of the market.

The development of the life science instrumentation market will be constrained by the high cost of instruments, a shortage of competent labor, technological limitations on qPCR and dPCR procedures, and the high cost of sophisticated microscopes. On the other hand, the expansion of the market can be threatened by the absence of research infrastructure in developing countries and price pressure.

Segment Analysis

The global Life Science Instrumentationmarket is segmented based on technology, application, end user and region.

The technology segment is expected to grow at the fastest CAGR during the forecast period(2023-2030)

Based on technology, the global Life Science Instrumentation market is segmented into Spectroscopy, Polymerase Chain Reaction (PCR), Chromatography, Flow Cytometry, Electrophoresis, Centrifuges and Others. Among these, The DNA polymerase's ability to build new DNA strands that are supporting to the provide template strand forms the basis of PCR. DNA polymerase requires a primer on which it may add the first nucleotide since it can only add a nucleotide onto an already-existing 3'-OH group.

This prerequisite allows the researcher to identify a particular area of the template sequence that they want to amplify. The specified sequence will accumulate in billions of copies at the end of the PCR cycle (amplicons). The segment is driven by the increasing prevalence of chronic and infectious diseases as well as the rising demand for precise and expedient disease diagnosis methods. Also, the segment is being driven by the development of technologically improved products and an increase in healthcare expenditure.

For instance, on January 2022, during Arab Health 2022, Irish diagnostics company HiberGene Diagnostics will introduce its PCR Adapt COVID-19 test. Ireland's leading manufacturer, developer, and producer of Molecular Diagnostics products is HiberGene, which holds an ISO certification. HiberGene's elite team created the ground-breaking PCR Adapt COVID-19 test as part of a plan to diversify the company's line of products.

On Feburaury 2023, To further advance healthcare and innovation in the Kingdom of Saudi Arabia, Tamer Healthcare, an integrated healthcare and wellness company with more than 100 years of established business in the Kingdom of Saudi Arabia, and Digital Diagnostics, the company behind IDx-DR, the first-ever FDA-cleared, fully autonomous AI system for the diagnosis of diabetic retinopathy, have announced a strategic partnership.

Geographical Penetration

The expansion of the industry is being facilitated by an increase in R&D efforts.

North America has established itself as the dominant market participant in the Life Science Instrumentations market. Life science and chemical instrumentation technology are used extensively in the pharmaceutical and biotechnology sectors in North America. Chemical instrumentation has shown to be an effective technological tool for a number of uses, including final production testing, pharmaceutical applications, environmental monitoring, and food testing.

Also, the expansion of the industry is being facilitated by an increase in R&D efforts. For instance, according to a 2021 update from the University of North Dakota, the National Institutes of Health (NIH) will continue to support the project through Phase II, according to the UND Center of Biomedical Research Excellence (CoBRE) in Host-Pathogen Interactions (HPI). The renewal of USD 10.7 million aims to further knowledge of how the body reacts to bacterial, viral, and parasitic infections that lead to acute and long-term inflammatory disorders. Thus, it is anticipated that increased R&D investment for various life sciences-related research will spur market expansion over the projection period.

Competitive Landscape

The major global players include Bio-Rad Laboratories Inc, Agilent Technologies Inc, PerkinElmer, Inc, F. Hoffmann-La Roche Ltd., Danaher Corporation, JEOL Ltd, Shimadzu Corporation, Becton, Dickinson & Company, HORIBA, Ltd. and Bruker Corporation.

COVID-19 Impact Analysis

By Technology

  • Spectroscopy
  • Polymerase Chain Reaction (PCR)
  • Chromatography
  • Flow Cytometry
  • Electrophoresis
  • Centrifuges
  • Others

By Application

  • Research
  • Clinical and Diagnostic

By End user

  • Pharma-Biotech
  • Agri and Food Industry
  • Hospitals & Diagnostic Labs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2022, A novel Fourier transform infrared spectrophotometer called the IRXross has been made available by Shimadzu Company. The sensitivity and resolution of this model are around twice as high as those of the IRAffinity-1S, its forerunner. The addition of the IR Pilot, an analytical help application that even novice users may use, has increased usability.
  • In October, 2021, SFDA has now approved a COVID-19 RT-PCR test that was developed by KAUST and first utilized in the United Kingdom. The service was launched at KAUST Health by KAUST company Noor DX. Noor DX offers a broad range of processing equipment using biotech diagnostics and is located in the Core Laboratories at KAUST. In the fight against COVID-19, this novel RT-PCR has the potential to be a game-changer, not just for Saudi Arabia but also for other nations looking for affordable, easily implemented diagnostics.
  • On August 2022, an agreement to acquire all of Curiosity Diagnostics' outstanding shares was announced by Bio-Rad Laboratories, Inc., a pioneer in life science research and clinical diagnostic products. For the molecular diagnostics business, Curiosity Diagnostics, a late-stage, pre-commercial platform company, is developing a sample-to-answer PCR system.

Why Purchase the Report?

  • To visualize the global Life Science Instrumentation- marketsegmentation based on Product, Technology, and region,as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerousdata points of Life Science Instrumentationmarket-level with allsegments.
  • PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key productsof all the major players.

The global Life Science Instrumentationmarketreport would provide approximately 53 tables,54figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Expanding public-private funding for life science research
      • 4.1.1.2. Increasing prevalence of chronic illnesses.
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. The high cost of instruments will hamper the growth of the market.
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. XX
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. PostCOVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. ByTechnology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Spectroscopy *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Polymerase Chain Reaction (PCR)
  • 7.4. Chromatography
  • 7.5. Flow Cytometry
  • 7.6. Electrophoresis
  • 7.7. Centrifuges
  • 7.8. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByTechnology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Research *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinical and Diagnostic

9. By End suer

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByTechnology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Pharmaceutical and Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Agri and Food Industry
  • 9.4. Hospitals & Diagnostic Labs

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis andY-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis andY-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Russia
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bio-Rad Laboratories Inc
    • 12.1.1. Company Overview
    • 12.1.2. ProductPortfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Agilent Technologies Inc
  • 12.3. PerkinElmer, Inc
  • 12.4. F. Hoffmann-La Roche Ltd.
  • 12.5. Danaher Corporation
  • 12.6. JEOL Ltd
  • 12.7. Shimadzu Corporation
  • 12.8. Becton, Dickinson & Company
  • 12.9. HORIBA, Ltd.,
  • 12.10. Bruker Corporation

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us